EON: Phase II trial of etigilimab (MPH313) in combination with nivolumab in patients with recurrent platinum-resistant clear cell ovarian cancer.

Ji Y. Son, Shannon N. Westin, Shuqi Wang et al.|Journal of Clinical Oncology|2025

Cited by 1